Main Text
Beta-2 microglobulin (B2M) is the light chain in the major histocompatibility complex (MHC) Class 1 molecule [1] , which is present in all nucleated cells. It has been suggested as an initiator of inflammation [2] , and is an early marker of diseases related to inflammation such as cardiovascular and renal disease [3, 4] . B2M is renally excreted and so the serum level increases in renal dysfunction. We and others have reported that serum B2M level predicts mortality in certain patient populations [3, [5] [6] [7] [8] [9] . We therefore examined whether serum B2M level predicted cardiovascular and all-cause mortality in a large nationally representative cohort.
Data from the Third National Health and Nutrition Examination Survey (NHANES III) were used [10] . NHANES III was conducted by the National Center for Health Statistics from 1988 to 1994 using a stratified multistage probability sample which represented the civilian non-institutionalized U.S. population. Participants gave written consent before participation, and ethical approval was obtained from the Human Subjects Committee of the U.S. Department of Health and Human Services.
Detailed study designs and measurements are provided in Supplementary Appendix.
The median B2M level in study participants was 2.01 mg/L (IQR=1.66-2.55).
Supplementary Table 1 Tables 3 and 4) showed similar findings, except that the association became insignificant after further adjustment for additional renal function biomarkers in the multicategorical model. Association of B2M level with cardiovascular mortality was consistent in the subgroups examined, except in the subgroups of participants with education level lower than high school, diabetes, hypertension, and current smoker ( Figure 2) . Thus, the main finding of this study was that serum B2M concentration predicted cardiovascular and all-cause mortality in a large cohort representative of the American general population. This was independent of renal function, cancer, history of heart disease, and cardiometabolic and mortality risk factors.
The association of B2M with mortality has been noted before [3, [5] [6] [7] [8] [9] . In our recent study, we showed that B2M is a predictor of mortality in diabetes patients [9] . As B2M reflects renal function, three studies examined its association of B2M with mortality in dialysis [6] [7] or uremic [3] patients. These studies showed that B2M is a predictor of all-cause [3, 7] and infectious disease [6] mortality in people with renal impairment, although the association with cardiovascular mortality was inconsistent [3, 6] . In 1,034 individuals aged 65 or above, B2M was shown to be associated with all-cause mortality [8] higher mortality. Our study extends the finding to people younger than 65 years, in whom a single biomarker to identify at risk persons would be especially valuable.
TheAtherosclerosis Risk in Communities (ARIC) Study examined several biomarkers of renal dysfunction (cystatin-C, BTP, and eGFR) and found that B2M had the strongest association with all-cause mortality in the general population [5] . In our analysis, we adjusted for renal function and showed that B2M was independently associated with cardiovascular and all-cause mortality (Supplementary Table 3 ).
In conclusion, serum B2M concentration is associated with a significant increased risk of cardiovascular (up to 6-fold) and all-cause (up to 4-fold) mortality. The increased risk is immediate and extends to at least 18 years, and is especially pronounced in people under the age of 65. These tantalizing findings call for validation in another 
